Scarica l'app Stockscreener
1.83
0.55%
0.01
Dopo l'orario di chiusura:
1.83
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.82
Aprire:
$1.9
Volume 24 ore:
23,319
Relative Volume:
0.16
Capitalizzazione di mercato:
$8.83M
Reddito:
-
Utile/perdita netta:
$-7.04M
Rapporto P/E:
-0.418
EPS:
-4.3784
Flusso di cassa netto:
$-6.17M
1 W Prestazione:
-3.17%
1M Prestazione:
+14.37%
6M Prestazione:
-5.18%
1 anno Prestazione:
-22.46%
Intervallo 1D:
$1.7635
$1.90
Intervallo di 1 settimana:
$1.7635
$1.95
Portata 52W:
$0.84
$2.68
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.83 | 8.83M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ALZN Q2 2026 Earnings: Wider-Than-Expected Loss for Pre-Revenue Biotech, Shares Still Edge HigherMargin Guidance - dars.gov.et
Alzamend Neuro regains Nasdaq listing compliance - Investing.com
Alzamend Neuro regains Nasdaq compliance - TradingView
Alzamend Neuro regains Nasdaq listing compliance By Investing.com - Investing.com UK
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - PR Newswire
Alzamend Neuro Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Alzamend Neuro Flags Substantial Going-Concern Doubt After Q1 Loss Widens - minichart.com.sg
Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary - TradingView
Alzamend Neuro (ALZN) raises cash but says conditions raise doubt it can keep operating - Stock Titan
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Shares DipCore Business Growth - dars.gov.et
ALZN Q1'26 Earnings: revenue estimate is 0 USD - tradingview.com
Alzamend Neuro Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Champions Oncology Inc. (CSBR) Peer Comparison – Compare with Others - Value Research
Alzamend Neuro (NASDAQ: ALZN) plans $25M preferred stock conversion vote - stocktitan.net
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Alzamend (ALZN) Results Versus Estimates: EPS Clears the Reported Estimate for the Current Session; Market Response: Shares Fall 4.29% in the Available RecordRevenue Guidance Range - vinanet.vn
IPO Databook: Alzamend Neuro (ALZN US)Aug 2026 - Smartkarma
Alzamend Neuro (ALZN) takes first step toward IPO with SEC filing - Stock Titan
Alzamend Neuro (ALZN) files amended insider trading report - Stock Titan
Alzamend’s lithium treatment data accepted for neuroscience meeting - Investing.com
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PR Newswire
Alzamend Neuro's AL001 fMRI abstract accepted for Neuroscience 2026 - scanx.trade
Alzamend (ALZN) Results Check: Reported EPS Tops Expectations for the Current Session; Market Reaction: Shares Move Higher 3.62% in the Current UpdateLong-Term Guidance - vinanet.vn
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Alzamend (ALZN) Results at a Glance: Profit Per Share Clears Its Benchmark on the Day; Post-Earnings Trading - vinanet.vn
Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com Canada
Alzamend to present lithium imaging data at Barcelona workshop - Investing.com South Africa
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - Investing News Network
Alzamend Neuro (ALZN) Advances 2.1% as Shares Hold Above $1.39 SupportDiagonal Spread Trade - vinanet.vn
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Remains CentralForward Guidance Trends - careplusvn.com
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com
Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks
Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView
ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.47 Highlights Cost DisciplineEarnings Call Q&A - dars.gov.et
Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - tipranks.com
ALZN|Alzamend Neuro Inc|Price:1.560|Chg%:-0.070 - TradingKey
Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView
TradingKey - TradingKey
Alzamend Neuro Inc (ALZN) Cash Flow - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro, Inc. Revenue Breakdown – NASDAQ:ALZN - TradingView
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALZN Q2 2026 Earnings: EPS Beat Surprises Market as Stock RalliesQuarterly Profit Report - vinanet.vn
Alzamend Neuro Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Alzamend Neuro Announces Passing of Board Director - The Globe and Mail
Alzamend Neuro FY 2026: Revenue $0 EPS $(2.63) — 10-K Summary - TradingView
ALZN Q2 2026 Earnings: EPS Beat of 70.46% Surprise, No Revenue Reported, Stock Rises 1.52%EPS Consistency Score - dars.gov.et
Alzamend Neuro Announces Passing of Director Fahey McGrath, Ph.D. in July 2026 – SEC 8-K Filing Details 7 - Minichart
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):